Successful desensitization to enfuvirtide after a hypersensitivity reaction in an HIV-1-infected man.
We report a case of successful, rapid desensitization to enfuvirtide after a hypersensitivity reaction in a man with highly drug-resistant human immunodeficiency virus type 1 infection. The patient was desensitized in a monitored intensive care unit and tolerated the rapid desensitization protocol without any serious adverse effects. This case illustrates the ability to safely desensitize patients with limited treatment options who require enfuvirtide therapy.
DeSimone
Joseph A
JA
Division of Infectious Diseases, Thomas Jefferson University, Philadelphia, PA 19107, USA. joseph.desimone@jefferson.edu
Ojha
Ambrish
A
Pathak
Rolee
R
Cohn
John
J
D000328:Adult; D004342:Drug Hypersensitivity / Q000628:therapy*; D000077560:Enfuvirtide; D015700:HIV Envelope Protein gp41 / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D023581:HIV Fusion Inhibitors / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D015658:HIV Infections / Q000188:drug therapy*; D015497:HIV-1; D006801:Humans; D008297:Male; D010446:Peptide Fragments / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D012074:Remission Induction
D015700:HIV Envelope Protein gp41; D023581:HIV Fusion Inhibitors; D010446:Peptide Fragments; D000077560:Enfuvirtide